Compare Synchrony Financial (SYF) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Synchrony Financial trades at $73.83 (market cap $23.40B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.5× Synchrony Financial's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Synchrony Financial for 28 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SYF | TAK | |
|---|---|---|
Market Cap | $23.40B | $58.16B |
Volume | 2,108,179 | 2,467,530 |
Sector | Financials | Health |
52-Week High | $88.47 | $19.05 |
52-Week Low | $63.78 | $13.23 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $23.64B | $86.04B |
Dividend Yield | 1.89% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYF trades at $71.93, down 0.32% on the day, with a bearish technical signal from moving averages. The stock is valued attractively with a P/E of 7.38 and P/S of 1.68, supported by strong profitability including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten estimates, and the company is expanding through partnerships like the Vetspire tie-up and OpenAI collaboration to enhance its digital payment solutions.
The outlook remains positive given the low valuation, high profitability, and strategic growth initiatives. Key risks include potential credit quality deterioration amid economic uncertainty and heavy investing cash outflows. Analyst consensus is bullish with a $88.18 price target, suggesting significant upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
